Key facts
- Class: GHRH analog. Synthetic growth hormone-releasing hormone (1-29), the biologically active fragment of the 44-amino-acid GHRH molecule; also written GRF(1-29)
- Mechanism: binds the GHRH receptor on pituitary somatotroph cells and stimulates the body's own pulsatile release of growth hormone
- Developer: originally developed and marketed as Geref (sermorelin acetate) by Serono
- Route: subcutaneous injection for treatment; also given as a single injection as a diagnostic stimulation test
- Approval status: previously FDA approved (Geref) for pediatric growth hormone deficiency and as a diagnostic agent, then withdrawn from the US market around 2008 for commercial reasons. No FDA-approved sermorelin product is marketed today; it exists only as a compounded preparation
- Evidence level: solid for raising growth hormone and IGF-1 and for pediatric deficiency; thin for the anti-aging, body-composition, and longevity claims sold by wellness clinics
- Most reported side effects: injection-site reactions (redness, pain, swelling); less commonly flushing, headache, dizziness, and altered taste
What is sermorelin?
Sermorelin is a shortened, synthetic version of growth hormone-releasing hormone (GHRH), the signal your hypothalamus normally sends to the pituitary to trigger growth hormone release.
Native GHRH is 44 amino acids long, but its full biological activity lives in the first 29. Sermorelin is exactly that fragment, GHRH(1-29), reproduced as a drug. It is not growth hormone, and it is not a synthetic mimic of some obscure molecule; it is a faithful copy of the front end of a hormone your body already makes and uses every night. That lineage is the single most important thing to understand about it, because it explains both what the peptide does and why the human data on it are unusually specific compared with most peptides marketed to consumers (PubMed 18031173).
Sermorelin arrived as a real, reviewed pharmaceutical, not a grey-market research chemical. It was studied in controlled trials, approved under the brand name Geref, and used in pediatric endocrinology clinics for years. It later left the US market for reasons that had nothing to do with whether it worked, and it re-entered public awareness through a very different door: anti-aging and "hormone optimization" clinics. That two-part story, a legitimate drug that became a wellness product, is what this page is really about.
How sermorelin works
Growth hormone is not secreted in a steady stream. The pituitary releases it in pulses, mostly at night, under two opposing controls: GHRH from the hypothalamus turns secretion on, and somatostatin turns it off. IGF-1, produced largely by the liver in response to growth hormone, feeds back to keep the whole system in check.
Sermorelin plugs into the "on" side of that circuit. It binds the GHRH receptor on the somatotroph cells of the anterior pituitary and stimulates them to synthesize and release stored growth hormone (PubMed 32257855). Crucially, it works through the body's existing machinery rather than bypassing it. If somatostatin is high, or if the pituitary has little to give, sermorelin's effect is blunted. That feedback dependence is the mechanistic basis for the common clinic claim that sermorelin produces a "more physiologic" growth hormone release than injecting growth hormone directly. The pulse still passes through the pituitary's own regulators, so it is harder to drive levels to a supraphysiologic extreme.
That same dependence is a ceiling, not just a safety feature. Because output is gated by the pituitary and by negative feedback, sermorelin cannot force growth hormone as high as direct somatropin injections can. It nudges a system; it does not override it. Native GHRH(1-29) also clears from the bloodstream quickly, in roughly 10 to 20 minutes, so a single injection produces a brief pulse rather than a sustained elevation. Later GHRH analogs were engineered specifically to get around that short half-life, which is where the comparison with CJC-1295 and tesamorelin comes in.
Geref: sermorelin's FDA history
This is the part that most consumer articles get muddled, so it is worth being precise.
Sermorelin acetate reached the US market as Geref. It was approved in two capacities. First, as a diagnostic agent: a single injection of sermorelin provokes a growth hormone response, and measuring that response helps assess whether the pituitary can secrete growth hormone at all, which is useful in working up suspected deficiency. Second, as a treatment: Geref was approved for the treatment of idiopathic growth hormone deficiency in children, given as a daily subcutaneous injection to support growth (PubMed 18031173).
Then it disappeared from pharmacy shelves. Around 2008 the manufacturer discontinued the branded product in the United States. This was a commercial decision, not a regulatory sanction. Sermorelin was never pulled for hurting anyone; the FDA's position, consistent with how it treats such withdrawals, was that the discontinuation was not for reasons of safety or effectiveness. Direct growth hormone (somatropin) had become the dominant, better-reimbursed therapy for pediatric deficiency, and a daily releasing-hormone injection was a harder product to sustain in that market. A drug can be perfectly effective and still fail commercially, and that is what happened here.
The consequence matters for anyone reading marketing copy today. "FDA approved" and "currently an FDA-approved product" are not the same statement. Sermorelin has an approval history. It does not have a marketed, FDA-reviewed product right now. Everything currently sold to consumers is a compounded preparation, which is a different regulatory category entirely.
Does sermorelin actually work?
The honest answer requires splitting the question by what "work" means, because sermorelin has strong evidence for some things and almost none for others.
Does it raise growth hormone? Yes, reliably. This is not in dispute. Provoking a growth hormone pulse is precisely why it functioned as a diagnostic agent, and it is documented across pediatric and adult studies.
Does it help children with growth hormone deficiency grow? Yes, this is the evidence that earned approval. In a controlled study of GH-deficient children, daily subcutaneous GHRH(1-29) increased growth velocity over the treatment period, the outcome that matters in pediatric endocrinology (PubMed 8772599). The review literature that supported Geref's use reaches the same conclusion: sermorelin was an effective, generally well-tolerated option for stimulating growth in appropriately selected deficient children (PubMed 18031173).
Does it deliver the benefits sold by anti-aging clinics? This is where the evidence thins to almost nothing. Raising a hormone level is a biomarker, not an outcome. The claims that draw most people to sermorelin, more lean muscle, less body fat, deeper sleep, sharper skin, better recovery, "reversed aging," are not backed by the kind of large, controlled, long-duration trials that would be needed to support them. The peptide's ability to bump growth hormone and IGF-1 is real; the leap from that to the marketed lifestyle outcomes is not demonstrated.
Sermorelin, aging, and the marketing gap
Growth hormone secretion falls with age, a decline sometimes called somatopause. That biological fact is the seed of the entire sermorelin anti-aging industry, and it is worth looking at what was actually studied.
The core human data come from small trials in older adults, not the glossy testimonials clinics quote. In one study, GHRH(1-29) given twice daily raised growth hormone and IGF-1 levels in older men back toward the range seen in younger men, showing that an aging pituitary still responds to the signal (PubMed 1379256). A separate trial of nightly GHRH(1-29) injections in healthy elderly men over six weeks likewise increased growth hormone output (PubMed 9005976). A clinical review later argued that a releasing-hormone approach could be a reasonable, more physiologic way to think about adult-onset growth hormone insufficiency, precisely because it preserves feedback control (PubMed 18046908).
Read carefully, though, those studies establish a narrow point: sermorelin can restore a hormonal signal in older people. They were small, short, mostly in men, and their endpoints were blood levels, not the things patients care about. They do not show that raising growth hormone in an otherwise healthy 55-year-old makes them leaner, stronger, sharper, or longer-lived. The wider literature on growth hormone in aging has been sobering on exactly this question: modest body-composition shifts have been reported, but so have meaningful side effects, and hard outcome benefits have been hard to pin down. Applying a therapy designed for genuine deficiency to healthy aging is a much bigger claim than the data support.
That is the marketing gap. Clinics take a legitimate mechanism and a couple of small hormonal studies and stretch them into promises about performance and longevity. The mechanism is real. The promises are not evidence. When you see the two run together, the sales copy is doing the work that a clinical trial should be doing.
Sermorelin vs CJC-1295, ipamorelin, and tesamorelin
Sermorelin is usually shopped alongside a small family of growth-hormone peptides, and they are not interchangeable. Two of them, CJC-1295 and tesamorelin, are GHRH analogs like sermorelin. Ipamorelin is a different kind of molecule entirely: a ghrelin-receptor agonist, or growth hormone secretagogue, that triggers a growth hormone pulse through a separate receptor (PubMed 9849822). Because it hits a different switch, ipamorelin is often paired with a GHRH analog in clinic protocols, on the theory that the two pathways add up (PubMed 32257855).
The sharpest way to see the differences is side by side.
| Peptide | Class | Receptor target | Duration of action | Regulatory status (US) |
|---|---|---|---|---|
| Sermorelin | GHRH analog, GHRH(1-29) | GHRH receptor | Short; clears in ~10-20 min | Previously FDA approved (Geref), withdrawn ~2008; now compounded only |
| CJC-1295 (with DAC) | Modified GHRH analog | GHRH receptor | Long; albumin-bound, acts for days | Never approved; sold as a research chemical |
| CJC-1295 (no DAC) / mod GRF(1-29) | Modified GHRH analog | GHRH receptor | Short, but more stable than sermorelin | Never approved; sold as a research chemical |
| Tesamorelin | Stabilized GHRH analog | GHRH receptor | Longer than sermorelin | FDA approved (Egrifta) for HIV-associated lipodystrophy |
| Ipamorelin | Ghrelin-receptor agonist (GH secretagogue) | GHS-R1a (ghrelin receptor) | Short, selective GH pulse | Never approved; sold as a research chemical |
Two takeaways stand out. First, sermorelin is the shortest-acting of the GHRH analogs, which is exactly why the others exist: CJC-1295 and tesamorelin were designed to survive longer in the blood. Tesamorelin is the only member of this group with a current FDA approval, earned in HIV-associated fat accumulation, where it produced measurable reductions in visceral fat in controlled trials (PubMed 20554713, PubMed 25038357). Second, "longer-acting" is not automatically "better." A sustained, non-pulsatile growth hormone elevation is more physiologically foreign than the brief pulse sermorelin produces, and the safety trade-offs of pushing the axis harder are not fully characterized for consumer use of any of these compounds.
None of this maps onto the growth-hormone story people know best. GLP-1 drugs work through a completely different hormone system; if that is what you were actually looking for, start with the overview of GLP-1 receptor agonists instead.
Sermorelin side effects reported in studies
Sermorelin's tolerability profile is one of the more reassuring parts of its record, largely because it was studied as a real drug in children under monitoring.
The most consistently reported side effect is a local reaction at the injection site: redness, pain, swelling, or itching. In the pediatric development program this occurred in roughly one in six treated children and was usually mild (PubMed 18031173). Less common reports across studies include flushing, headache, dizziness, nausea, an altered sense of taste, paleness, and, in children, hyperactivity. Because sermorelin transiently stimulates the pituitary, small, short-lived rises in other pituitary-linked hormones have also been noted. Serious adverse events were uncommon in the trials that supported approval (PubMed 8772599).
Two honest caveats belong next to that clean-looking list. First, almost all of the controlled safety data come from children treated for genuine deficiency, not from healthy adults using it for anti-aging, and the two populations are not equivalent. Second, there is no long-term safety surveillance for chronic sermorelin use in healthy people, because that use was never studied at scale or tracked after marketing the way an approved product is. Raising growth hormone and IGF-1 is not consequence-free, and the theoretical concerns that attach to the growth hormone axis, including effects on glucose handling and on tissue growth, apply here in proportion to how hard and how long the axis is pushed. Absence of reported harm in short pediatric trials is not the same as proven safety for years of adult use.
Is sermorelin FDA approved today?
No FDA-approved sermorelin product is currently marketed in the United States. The approval history is real, but it belongs to a discontinued branded product.
What fills the gap is compounding. Licensed compounding pharmacies have prepared sermorelin on a prescription, which is how the peptide reaches the anti-aging and hormone-clinic market. Compounded drugs are not FDA-approved and do not go through the agency's review for safety, efficacy, or manufacturing quality; they occupy a specific, conditional legal lane meant for individualized patient needs, not for mass-marketed lifestyle products. That lane has been actively contested. The FDA has scrutinized which peptides may lawfully be compounded, and the status of sermorelin and related peptides has shifted as those reviews have proceeded, which is why availability has changed over time and why blanket claims that it is "legal" or "illegal" both oversimplify.
The practical bottom line: sermorelin is neither an approved off-the-shelf medicine nor an obvious research chemical. It sits in a prescription-and-compounding grey zone whose boundaries move. Vials sold online outside that framework carry all the usual unregulated-supply risks, no verified identity, purity, or sterility. The broader legal picture for this whole category is covered in are peptides legal. PepMate does not sell peptides, recommend suppliers, or help anyone obtain any substance.
What is worth logging on a GH peptide
If you are working with a clinician on any growth-hormone peptide, the value of the therapy is easier to judge when you are actually keeping records instead of relying on memory and marketing.
The things that consistently earn their place in a log: the date and site of each injection and how you are rotating sites, any lab values your clinician orders, especially IGF-1, since that is the biomarker this class moves, and a timestamped note whenever you notice sleep changes, injection-site reactions, water retention, joint aches, or shifts in appetite. Weight and body-composition trends, energy, and sleep quality round it out. Because so much of the sermorelin story is a gap between claimed and real benefit, a plain personal record is the one thing that lets you and your clinician see whether anything measurable is actually happening on your end, rather than trusting a testimonial.
That is the entire job of PepMate: it holds the record and decides nothing for you. For the general approach, see how to track peptides, and the peptide Q&A library answers the common questions in short form.
Frequently asked questions
Is sermorelin FDA approved?
Not currently. Sermorelin was FDA approved in the 1990s and marketed as Geref for diagnosing and treating growth hormone deficiency in children, but the manufacturer withdrew it from the US market around 2008 for commercial reasons, not because of safety or efficacy problems. There is no FDA-approved sermorelin product on the US market today; it is available only as a compounded preparation.
Does sermorelin actually work?
It depends on the goal. Sermorelin reliably prompts the pituitary to release growth hormone and raises IGF-1, which is well documented in children with growth hormone deficiency and in small studies of older adults. What is not well established is whether that translates into the muscle, fat, sleep, and anti-aging benefits marketed by wellness clinics. Those outcome claims outrun the published evidence.
What is the difference between sermorelin and CJC-1295?
Both are GHRH analogs that act on the same pituitary receptor, but sermorelin is essentially native GHRH(1-29) and clears from the blood in roughly 10 to 20 minutes. CJC-1295 was engineered for stability; the modified version with DAC binds albumin and can act for days. Sermorelin has an FDA-approval history and human trial data. CJC-1295 has never been approved and circulates only as a research chemical.
Is sermorelin the same as HGH?
No. HGH, or somatropin, is growth hormone itself, injected directly to raise blood levels. Sermorelin is a releasing hormone: it signals your own pituitary to make and secrete growth hormone in natural pulses, subject to the body's feedback controls. Because the pituitary still regulates the output, sermorelin cannot push growth hormone as high as direct HGH injections can.
What are the side effects of sermorelin?
The most common reported side effect is a reaction at the injection site, such as redness, pain, or swelling, seen in roughly one in six children in the pediatric trials. Less common reports include flushing, headache, dizziness, nausea, altered taste, and hyperactivity. Serious adverse events were uncommon in the studies that supported its approval, but there is no long-term safety data for anti-aging use.
Is sermorelin legal?
Sermorelin occupies a grey zone. There is no FDA-approved sermorelin product, but licensed compounding pharmacies have prepared it on a prescription. Its regulatory footing has been unsettled, with the FDA scrutinizing whether it qualifies for compounding, and access has shifted over time. It is not an approved over-the-counter product or a research chemical you can lawfully buy for personal use.
How long does sermorelin take to work?
Sermorelin raises growth hormone within minutes of an injection, which is why it was used as a diagnostic stimulation test. The changes people actually care about are slower and far less certain. In its pediatric approval, growth was assessed over months of daily therapy. For the body-composition claims made by clinics, there is no reliable trial timeline because those outcomes have not been convincingly demonstrated.
Was sermorelin banned by the FDA?
No. Sermorelin was not banned. The branded product Geref was discontinued around 2008 for commercial reasons, and the FDA has stated the withdrawal was not for reasons of safety or effectiveness. That is different from a ban. It does mean, though, that no FDA-reviewed sermorelin product is currently marketed, so today's supply comes from compounding pharmacies.
Sources
Every claim above traces to peer-reviewed literature indexed on PubMed:
- Sermorelin: a review of its use in the diagnosis and treatment of children with growth hormone deficiency — PubMed 18031173
- Once daily subcutaneous growth hormone-releasing hormone therapy in GH-deficient children — PubMed 8772599
- Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men — PubMed 1379256
- Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men — PubMed 9005976
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? — PubMed 18046908
- The role of growth hormone secretagogues in the modern clinic — PubMed 32257855
- Ipamorelin, the first selective growth hormone secretagogue — PubMed 9849822
- Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation — PubMed 20554713
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients — PubMed 25038357
- Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 — PubMed 16352683